Irina Vodneva
- Xeris Biopharma (NASDAQ:XERS) said that the U.S. Patent and Trademark Office issued a patent covering its XeriSol formulations.
- The Patent Number 11,590,205 is titled 'Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents.'
- The claims in the patent cover certain pharmaceutical formulations in Xeris' Gvoke product line, methods of use of such formulations in treating hypoglycemia, and methods of manufacturing the therapeutic formulations.
- "The addition of this new patent further strengthens our intellectual property position in the XeriSol™ platform portion of our portfolio and has claims that will cover the Gvoke formulation, which is in all our currently marketed Gvoke products," said Xeris' Chairman and CEO Paul Edick.
- XERS +1.27% to $2.40 premarket April 18